Q-omics provides the consensus-scored GTF2H5 profile across patient tissues and cancer cell-line models. GTF2H5 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, GTF2H5 is differentially expressed in 10, with the highest sampling consensus in KICH. Additionally, GTF2H5 RNA expression shows 17,391 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight HNSC, KICH, and UVM as cancer lineages where GTF2H5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GTF2H5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GTF2H5 survival associations across molecular data types. GTF2H5 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (2) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GTF2H5 RNA expression–survival associations across cancer types. High GTF2H5 expression shows unfavorable associations in HNSC, KICH, OV, UVM and UCS, but favorable associations in THCA. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for GTF2H5 RNA expression.
This table summarizes GTF2H5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 5. The strongest signals are observed in KICH for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for GTF2H5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GTF2H5 shows lower tumor expression in KICH and KIRC and higher tumor expression in LIHC, HNSC, CHOL and COAD. The KICH box plot shows higher GTF2H5 RNA expression in normal versus tumor tissue (log2 FC = −1.567, t-test p < 0.001).
This table shows molecular features associated with GTF2H5 in patient tissues and cancer cell lines. In patient samples, GTF2H5 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, GTF2H5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and LUNG_NSCLC_LUSC.
